Filing Flows › Comparisons › TARS vs ALEC
Tarsus Pharmaceuticals vs Alector: TARS and ALEC compared
Tarsus Pharmaceuticals is the larger company: $195M of revenue in its latest quarter (Q3 2026) against $163M for Alector (Q3 2026). Alector is growing faster (50× against +64% a year earlier). Alector is more profitable, with an operating margin of 76.0% against -340.3%.
Where the money goes: TARS and ALEC
Tarsus Pharmaceuticals (TARS) · Q3 2026
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Alector (ALEC) · Q3 2026
Alector, Q3 2026: revenue $163M (50× year over year), operating margin 76.0%, net earnings $125M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
| Tarsus Pharmaceuticals (TARS) | Alector (ALEC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $195M | $163M |
| Revenue growth, Y/Y | +64% | 50× |
| Operating margin | -340.3% | 76.0% |
| Net earnings | −$668M | $125M |
| Net margin | -343.5% | 76.5% |
| Operating cash flow | −$6.0M | −$24.2M |
Questions
Which is bigger, Tarsus Pharmaceuticals or Alector?
Tarsus Pharmaceuticals is the larger company: $195M of revenue in its latest quarter (Q3 2026) against $163M for Alector (Q3 2026).
Is Tarsus Pharmaceuticals or Alector growing faster?
Alector is growing faster (50× against +64% a year earlier).
Which is more profitable, Tarsus Pharmaceuticals or Alector?
Alector is more profitable, with an operating margin of 76.0% against -340.3%.
More: Tarsus Pharmaceuticals earnings · how Tarsus Pharmaceuticals makes money · Alector earnings · how Alector makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.